How to Trip Rapid Review

Step 1: Select articles relevant to your search (remember the system is only optimised for single intervention studies)

Step 2: press

Step 3: review the result, and maybe amend the or if you know better! If we're unsure of the overall sentiment of the trial we will display the conclusion under the article title. We then require you to tell us what the correct sentiment is.

28,772 results for

prostate cancer from:2010 to:2017

by
...
Alerts

Export results

Use check boxes to select individual results below

SmartSearch available

Trip's SmartSearch engine has discovered connected searches & results. Click to show

1. The clinical effectiveness and cost-effectiveness of the PROGENSA prostate cancer antigen 3 assay and the Prostate Health Index in the diagnosis of prostate cancer: a systematic review and economic evaluation

The clinical effectiveness and cost-effectiveness of the PROGENSA prostate cancer antigen 3 assay and the Prostate Health Index in the diagnosis of prostate cancer: a systematic review and economic evaluation The clinical effectiveness and cost-effectiveness of the PROGENSA® prostate cancer antigen 3 assay and the Prostate Health Index in the diagnosis of prostate cancer: a systematic review and economic evaluation Journals Library An error occurred retrieving content to display, please try

2015 NIHR HTA programme

2. Randomised controlled trial: Similar prostate cancer and all-cause mortality in men with localised prostate cancer undergoing surgery or radiation therapy versus active monitoring at 10?years of follow-up

Randomised controlled trial: Similar prostate cancer and all-cause mortality in men with localised prostate cancer undergoing surgery or radiation therapy versus active monitoring at 10?years of follow-up Similar prostate cancer and all-cause mortality in men with localised prostate cancer undergoing surgery or radiation therapy versus active monitoring at 10 years of follow-up | BMJ Evidence-Based Medicine We use cookies to improve our service and to tailor our content and advertising to you (...) prostate cancer and all-cause mortality in men with localised prostate cancer undergoing surgery or radiation therapy versus active monitoring at 10 years of follow-up Article Text Therapeutics/Prevention Randomised controlled trial Similar prostate cancer and all-cause mortality in men with localised prostate cancer undergoing surgery or radiation therapy versus active monitoring at 10 years of follow-up Philipp Dahm 1 , 2 , Dragan Ilic 3 , Timothy Wilt 4 , 5 Statistics from Altmetric.com Commentary

2017 Evidence-Based Medicine

3. Padeliporfin (Tookad) - prostate cancer / Prostatic Neoplasms

Padeliporfin (Tookad) - prostate cancer / Prostatic Neoplasms 30 Churchill Place ? Canary Wharf ? London E14 5EU ? United Kingdom An agency of the European Union Telephone +44 (0)20 3660 6000 Facsimile +44 (0)20 3660 5520 Send a question via our website www.ema.europa.eu/contact 14 September 2017 EMA/644309/2017 Committee for Medicinal Products for Human Use (CHMP) Assessment report TOOKAD International non-proprietary name: padeliporfin Procedure No. EMEA/H/C/004182/0000 Note Assessment report (...) an application for marketing authorisation to the European Medicines Agency (EMA) for Tookad, through the centralised procedure falling within the Article 3(1) and point 3 of Annex of Regulation (EC) No 726/2004. The eligibility to the centralised procedure was agreed upon by the EMA/CHMP on 26 March 2015. The applicant applied for the following indication: Tookad is indicated for the treatment of low-risk localised prostate cancer. Tookad is indicated in adult males. The legal basis for this application

2017 European Medicines Agency - EPARs

4. Biodegradable spacer insertion to reduce rectal toxicity during radiotherapy for prostate cancer

Biodegradable spacer insertion to reduce rectal toxicity during radiotherapy for prostate cancer Biodegr Biodegradable spacer insertion to reduce rectal adable spacer insertion to reduce rectal to toxicity during r xicity during radiother adiotherap apy for prostate cancer y for prostate cancer Interventional procedures guidance Published: 23 August 2017 nice.org.uk/guidance/ipg590 Y Y our responsibility our responsibility This guidance represents the view of NICE, arrived at after careful (...) Recommendations 1.1 Current evidence on the safety and efficacy of insertion of a biodegradable spacer to reduce rectal toxicity during radiotherapy for prostate cancer is adequate to support the use of this procedure provided that standard arrangements are in place for clinical governance, consent and audit. © NICE 2018. All rights reserved. Subject to Notice of rights (https://www.nice.org.uk/terms-and- conditions#notice-of-rights). Page 1 of 81.2 The procedure should only be done by clinicians

2017 National Institute for Health and Clinical Excellence - Interventional Procedures

5. Irreversible electroporation for treating prostate cancer

Irreversible electroporation for treating prostate cancer Irre Irrev versible electropor ersible electroporation for treating prostate ation for treating prostate cancer cancer Interventional procedures guidance Published: 21 December 2016 nice.org.uk/guidance/ipg572 Y Y our responsibility our responsibility This guidance represents the view of NICE, arrived at after careful consideration of the evidence available. When exercising their judgement, healthcare professionals are expected to take (...) good relations. Nothing in this guidance should be interpreted in a way that would be inconsistent with compliance with those duties. Commissioners and providers have a responsibility to promote an environmentally sustainable health and care system and should assess and reduce the environmental impact of implementing NICE recommendations wherever possible. 1 1 Recommendations Recommendations 1.1 Current evidence on the safety and efficacy of irreversible electroporation for treating prostate cancer

2017 National Institute for Health and Clinical Excellence - Interventional Procedures

6. Brachytherapy for Patients with Prostate Cancer: American Society of Clinical Oncology/Cancer Care Ontario Joint Guideline Update

Brachytherapy for Patients with Prostate Cancer: American Society of Clinical Oncology/Cancer Care Ontario Joint Guideline Update Genitourinary Cancer | ASCO Search form Search ASCO Family of Sites ASCOconnection.org features blogs from ASCO members, the online version of the membership magazine, a discussion area, working groups, and links to the ASCO Membership Directory, Career Center, and Volunteer Portal. ASCO’s growing roster of cutting-edge journals serves readers as the most credible (...) , authoritative, peer-reviewed resources for significant clinical oncology research and research that informs the delivery of efficient, high-quality cancer care across the globe. ASCO Practice Central helps oncology professionals navigate a complicated and ever-changing practice environment—while providing high-quality patient care. ASCO University serves as a comprehensive eLearning and mobile learning center that supports lifelong learning for physicians, advanced practice providers, and patient educators

2017 Cancer Care Ontario

7. Diagnosing prostate cancer: PROGENSA PCA3 assay and Prostate Health Index

Diagnosing prostate cancer: PROGENSA PCA3 assay and Prostate Health Index Diagnosing prostate cancer: PR Diagnosing prostate cancer: PROGENSA OGENSA PCA3 assa PCA3 assay and Prostate Health Inde y and Prostate Health Index x Diagnostics guidance Published: 3 June 2015 nice.org.uk/guidance/dg17 © NICE 2018. All rights reserved. Subject to Notice of rights (https://www.nice.org.uk/terms-and-conditions#notice-of- rights).Y Y our responsibility our responsibility This guidance represents the view (...) possible. Diagnosing prostate cancer: PROGENSA PCA3 assay and Prostate Health Index (DG17) © NICE 2018. All rights reserved. Subject to Notice of rights (https://www.nice.org.uk/terms-and- conditions#notice-of-rights). Page 2 of 51Contents Contents 1 Recommendation 4 2 The technologies 5 3 Clinical need and practice 6 The problem addressed 6 The condition 7 The diagnostic and care pathways 7 4 The diagnostic tests 10 The interventions 10 The comparator: clinical assessment or clinical assessment plus

2015 National Institute for Health and Clinical Excellence - Diagnostics Guidance

To help you find the content you need quickly, you can filter your results via the categories on the right-hand side >>>>